Semaglutide for fatty liver disease: what the ESSENCE trial and FDA approval mean

TL;DR

In August 2025 the FDA approved Wegovy (semaglutide 2.4 mg) as the first GLP-1 therapy specifically for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. The Phase 3 ESSENCE trial showed 63% of patients achieved MASH resolution without worsening fibrosis, versus 34% on placebo - a number-needed-to-treat of roughly 3 to 4. Around 15 million US adults are estimated to have MASH.

Most people taking Ozempic or Wegovy for weight loss or diabetes don't think about their liver. But fatty liver disease is deeply intertwined with obesity and insulin resistance - the same conditions GLP-1 medications treat. The ESSENCE data and subsequent FDA approval changed the medical conversation around semaglutide's indications significantly.

What MASH is and why it matters

MASH stands for metabolic dysfunction-associated steatohepatitis. Until 2023 it was called NASH (non-alcoholic steatohepatitis) - the name was changed to better reflect its metabolic root causes. It is a progressive form of fatty liver disease where excess fat in the liver triggers inflammation, which in turn causes scarring (fibrosis). Left untreated, MASH can progress to cirrhosis, liver failure, and liver cancer.

Approximately 6% of US adults - around 15 million people - have MASH with meaningful fibrosis. A much larger number (25 to 38% of adults) have the milder preceding condition, MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD), where fat accumulates but inflammation hasn't taken hold yet. MASH specifically is the stage where the disease is actively destructive and where treatment becomes urgent.

Until 2024, there were no approved drug treatments for MASH. That changed with the approval of Rezdiffra (resmetirom) in March 2024 - the first approved MASH drug - and then Wegovy in August 2025 as the first GLP-1 therapy approved for MASH.

What the ESSENCE trial found

ESSENCE was a Phase 3 randomized controlled trial assessing semaglutide 2.4 mg weekly (the same dose used for weight loss) in adults with confirmed MASH and moderate to advanced liver fibrosis (F2 or F3 on the fibrosis staging scale). The primary endpoints were measured at 72 weeks via liver biopsy.

The results at week 72:

MASH resolution without worsening fibrosis: 63% on semaglutide vs 34% on placebo - an absolute difference of roughly 25 to 30 percentage points
Number needed to treat: approximately 3 to 4 - meaning for every 3 to 4 patients treated, one achieves MASH resolution who would not have on placebo alone
Fibrosis improvement of at least one stage: 33% on semaglutide vs 20% on placebo - a number needed to treat of approximately 6 to 8
Both MASH resolution and fibrosis improvement: absolute benefit of approximately 15 to 17 percentage points favouring semaglutide

Weight loss was also substantial: approximately 10 to 11% on semaglutide versus 2% on placebo. Beyond the liver, semaglutide improved HbA1c, blood pressure, triglycerides, HDL cholesterol, and the inflammatory marker hs-CRP.

How semaglutide helps the liver

There's an interesting scientific debate here that the ESSENCE authors themselves flagged. GLP-1 receptors are not expressed in liver tissue - at least not in significant quantities. So how is semaglutide improving liver pathology directly?

The leading hypothesis is a dual-pathway model. The primary driver is weight loss: losing 10% or more of body weight is well established as sufficient to reduce liver fat and inflammation independently of any drug mechanism. Semaglutide reliably produces this level of weight loss in most patients.

But the fibrosis improvement data - where scarring is actually reversing - may involve additional time and mechanisms. Some researchers propose indirect hepatic effects through improved adipose tissue metabolism (fat cells becoming less inflammatory when the body loses weight), reduced insulin resistance enabling the liver to process fat more normally, and systemic reductions in inflammatory signalling that affect the liver alongside other organs.

Whether semaglutide has any direct liver action independent of weight loss remains an open question that ongoing research is designed to answer.

Who this approval covers

The FDA approval specifically covers adults with MASH and moderate to advanced fibrosis (F2 or F3). It does not cover:

MASLD without inflammation (simple fatty liver)
MASH with early fibrosis (F1) or no fibrosis (F0)
MASH with cirrhosis (F4) - this population was not studied in ESSENCE

In practice, many people currently using Wegovy for weight loss who also happen to have MASH are already receiving the benefit, even if their prescription doesn't list MASH as the indication. The drug is the same; the dosing is the same. What changes is whether insurers can now be billed for the MASH indication - which may affect coverage decisions for some patients.

What this means if you have fatty liver and are on GLP-1 medications

If you've been told you have fatty liver, NAFLD, MASLD, or NASH - and you're already on semaglutide or tirzepatide for weight loss or diabetes - you may be treating two conditions simultaneously. That's worth knowing and worth discussing with your hepatologist or GP.

A few practical points:

Liver function tests (ALT, AST) and liver imaging at baseline and periodically while on treatment give useful feedback on whether your liver is responding
The ESSENCE data is for semaglutide specifically - tirzepatide data in MASH is still emerging, though the metabolic effects of tirzepatide suggest similar or greater liver benefit is plausible
Nutrition matters alongside medication: high-fructose diets and alcohol both independently worsen liver fibrosis; addressing these while on GLP-1 therapy compounds the benefit
Vitamin E and vitamin D have separate evidence bases in MASH management - both are nutrients at increased depletion risk on GLP-1 medications, which makes monitoring and supplementation relevant in this population specifically

At GLP-1 Shield, we design our formulations around the nutrients GLP-1 users most commonly become deficient in - including vitamin D and other fat-soluble vitamins relevant to liver health. People with MASH are a population where nutrient gaps and drug benefits are especially tightly interlinked.

The broader picture: GLP-1 expanding beyond weight loss

The MASH approval is one of several expansions in semaglutide's approved indications. The drug is now approved for type 2 diabetes (Ozempic), weight loss (Wegovy), cardiovascular risk reduction (SELECT trial - 20% reduction in major adverse cardiovascular events), and now MASH. Kidney protection data from the FLOW trial adds another dimension.

This multi-organ benefit profile is why GLP-1 medications are being described as a potential paradigm shift in metabolic medicine - not because they're magic, but because obesity and insulin resistance connect to so many disease pathways simultaneously that a drug targeting those root causes can produce improvements across multiple organ systems at once.

Worried about your own nutrient gaps on GLP-1?

Be among the first to try the scientifically designed GLP-1 Shield supplements.

Frequently asked questions

Is Wegovy approved for fatty liver disease?: Yes. The FDA approved Wegovy (semaglutide 2.4 mg weekly) for the treatment of MASH with moderate to advanced liver fibrosis in August 2025. This was the first GLP-1 therapy approved specifically for liver disease, following Rezdiffra (resmetirom) which received the first-ever MASH approval in March 2024.
How effective is semaglutide for MASH?: In the Phase 3 ESSENCE trial, 63% of patients on semaglutide 2.4 mg achieved MASH resolution without worsening fibrosis at 72 weeks, compared to 34% on placebo. One in three patients showed at least one stage of fibrosis improvement. The number needed to treat for MASH resolution was approximately 3 to 4 - meaning a very strong treatment effect by clinical standards.
Can Ozempic help with fatty liver disease?: Ozempic uses the same active ingredient as Wegovy (semaglutide) but at a lower approved dose (up to 2 mg for diabetes vs 2.4 mg for weight loss). While the ESSENCE approval was for Wegovy's 2.4 mg dose, earlier studies showed liver fat reduction with lower semaglutide doses as well. If you have fatty liver and are on Ozempic, discuss with your doctor whether dose optimisation is appropriate.
Does tirzepatide also help with fatty liver?: Tirzepatide (Mounjaro, Zepbound) produces greater weight loss than semaglutide on average, and liver fat reduction tends to follow weight loss closely. Clinical trials assessing tirzepatide specifically in MASH are ongoing. The metabolic effects suggest meaningful liver benefit is likely, but dedicated Phase 3 MASH data for tirzepatide has not yet been published as of June 2026.